Growth Metrics

DBV Technologies (DBVT) Cash from Investing Activities (2016 - 2026)

DBV Technologies (DBVT) reported Cash from Investing Activities of -$300000.0 for Q1 2026, up 25.0% year-over-year from -$240000.0 in Q1 2025, and up 58.04% on a QoQ basis from -$715000.0 in Q4 2025.

DBV Technologies (DBVT) has 10 years of Cash from Investing Activities data on file, last reported at -$300000.0 in Q1 2026.

  • Quarterly Cash from Investing Activities rose 25.0% year-over-year to -$300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 230.15% YoY) and the FY2025 annual result came in at -$1.4 million, down 80.85% from the prior year.
  • Cash from Investing Activities advanced to -$300000.0 in Q1 2026 per DBVT's latest filing, from -$715000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $793000.0 in Q4 2024 and bottomed at -$2.1 million in Q1 2024.
  • The 5-year median for Cash from Investing Activities is -$187000.0 (2023), against an average of -$196117.6.
  • Peak annual rise in Cash from Investing Activities reached 524.06% in 2024, while the deepest fall reached 5176.19% in 2024.
  • Tracing DBVT's Cash from Investing Activities over 5 years: stood at -$34000.0 in 2022, then tumbled by 450.0% to -$187000.0 in 2023, then jumped by 524.06% to $793000.0 in 2024, then slumped by 190.16% to -$715000.0 in 2025, then jumped by 58.04% to -$300000.0 in 2026.
  • Per Business Quant, the three latest DBVT Cash from Investing Activities figures stand at -$300000.0 (Q1 2026), -$715000.0 (Q4 2025), and -$241000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.89 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -25.54 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn -300,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -300,000.00
Mar 31, 2026 -300,000.00
Dec 31, 2025 -715,000.00
Dec 31, 2025 -715,000.00
Sep 30, 2025 -241,000.00
Sep 30, 2025 -241,000.00
Jun 30, 2025 -13,000.00
Jun 30, 2025 -13,000.00
Mar 31, 2025 -400,000.00
Mar 31, 2025 -400,000.00
Dec 31, 2024 793,000.00
Dec 31, 2024 793,000.00
Sep 30, 2024 -109,000.00
Sep 30, 2024 -109,000.00
Jun 30, 2024 691,000.00
Jun 30, 2024 691,000.00
Mar 31, 2024 -2.13 Mn
Mar 31, 2024 -2.13 Mn
Dec 31, 2023 -187,000.00
Dec 31, 2023 -187,000.00
Sep 30, 2023 -322,000.00
Sep 30, 2023 -322,000.00
Jun 30, 2023 -341,000.00
Jun 30, 2023 -341,000.00
Mar 31, 2023 42,000.00
Mar 31, 2023 42,000.00
Dec 31, 2022 -34,000.00
Dec 31, 2022 -34,000.00
Sep 30, 2022 152,000.00
Sep 30, 2022 152,000.00
Jun 30, 2022 -229,000.00
Jun 30, 2022 -229,000.00
Mar 31, 2022 11,000.00
Mar 31, 2022 11,000.00
Dec 31, 2021 -474,000.00
Dec 31, 2021 -474,000.00
Sep 30, 2021 54,000.00
Sep 30, 2021 54,000.00
Jun 30, 2021 172,000.00
Jun 30, 2021 172,000.00
Mar 31, 2021 -185,000.00
Mar 31, 2021 -185,000.00
Dec 31, 2020 -633,000.00
Dec 31, 2020 -633,000.00
Sep 30, 2020 -782,000.00
Sep 30, 2020 -782,000.00
Jun 30, 2020 -520,000.00
Jun 30, 2020 -520,000.00
Mar 31, 2020 -930,000.00
Mar 31, 2020 -930,000.00
Dec 31, 2018 -9.86 Mn
Dec 31, 2018 -9.86 Mn
Dec 31, 2017 -9.22 Mn
Dec 31, 2017 -9.22 Mn
Dec 31, 2016 -8.96 Mn
Dec 31, 2016 -8.96 Mn